Austin Kulasekararaj, ASH 2018 – Treatments for Paroxysmal Nocturnal Hemoglobinuria
In this interview filmed at ASH 2018, Dr Austin Kulasekararaj discusses the phase III non-inferiority study investigating ravulizumab (ALXN1210) versus eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria in patients currently treated with eculizumab. He then goes on to discuss how he thinks these findings will affect management strategies for patients with paroxysmal nocturnal hemoglobinuria in the future.
Questions:
1. What was the background and rationale behind the phase III non-inferiority study investigating ravulizumab (ALXN1210) versus eculizumab in adult patients with paroxysmal nocturnal hemoglobinuria currently treated with eculizumab? (0:10)
2. What were the key efficacy and safety findings? (1:51)
3. What are the next steps in this area of research over the coming years? (2:47)
4. How do you think these findings will contribute to management strategies for patients with paroxysmal nocturnal hemoglobinuria in the future? (3:38)
5. What other exciting developments have been presented at ASH 2018 for this indication? (4:28)
Speaker’s disclosures: Austin Kulasekararaj has participated in speaker’s bureau for Alexion, Celgene and Novartis, and received honoraria from Alexion, Amgen, Celgene, Novartis and Ra Pharma.
Filmed at the 60th American Society of Hematology (ASH) 2018 Annual Meeting, San Diego, CA, US, December 1–4, 2018.
